Patient Outcomes: Sarilumab Beats Adalimumab

(MedPage Today) -- Pain, physical function, and health-related quality-of-life measures favored the IL-6 blocker

Source: MedPage Today Primary Care - June 20, 2018 Category: Primary Care Source Type: news